Rapid onset of action and reduced nasal hyperreactivity: new targets in allergic rhinitis management
Abstract Background This article summarizes a EUFOREA symposium, presented during the European Rhinology Research Forum in Brussels (9–10 November 2017; https://www.rhinologyresearch.eu/) which focused on novel pathways and therapeutic approaches in allergic rhinitis (AR). Main body AR remains under...
Main Authors: | C. Bachert, J. Bousquet, P. Hellings |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-06-01
|
Series: | Clinical and Translational Allergy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13601-018-0210-2 |
Similar Items
-
The complex pathophysiology of allergic rhinitis: scientific rationale for the development of an alternative treatment option
by: Leif Bjermer, et al.
Published: (2019-04-01) -
Allergic rhinitis and asthma symptoms in a real-life study of MP-AzeFlu to treat multimorbid allergic rhinitis and asthma
by: David Price, et al.
Published: (2020-08-01) -
Superior effect of MP-AzeFlu than azelastine or fluticasone propionate alone on reducing inflammatory markers
by: Jordi Roca-Ferrer, et al.
Published: (2018-12-01) -
A review of the clinical efficacy and safety of MP-AzeFlu, a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate, in clinical studies conducted during different allergy seasons in the US
by: Prenner BM
Published: (2016-07-01) -
Bronchial hyperreactivity and spirometric impairment in polysensitized patients with allergic rhinitis
by: Tosca Maria A, et al.
Published: (2004-03-01)